159 related articles for article (PubMed ID: 26014311)
1. Long-term outcomes of analogue insulin compared with NPH for patients with type 2 diabetes mellitus.
Prentice JC; Conlin PR; Gellad WF; Edelman D; Lee TA; Pizer SD
Am J Manag Care; 2015 Mar; 21(3):e235-43. PubMed ID: 26014311
[TBL] [Abstract][Full Text] [Related]
2. Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus.
Horvath K; Jeitler K; Berghold A; Ebrahim SH; Gratzer TW; Plank J; Kaiser T; Pieber TR; Siebenhofer A
Cochrane Database Syst Rev; 2007 Apr; (2):CD005613. PubMed ID: 17443605
[TBL] [Abstract][Full Text] [Related]
3. Association of Initiation of Basal Insulin Analogs vs Neutral Protamine Hagedorn Insulin With Hypoglycemia-Related Emergency Department Visits or Hospital Admissions and With Glycemic Control in Patients With Type 2 Diabetes.
Lipska KJ; Parker MM; Moffet HH; Huang ES; Karter AJ
JAMA; 2018 Jul; 320(1):53-62. PubMed ID: 29936529
[TBL] [Abstract][Full Text] [Related]
4. Capitalizing on prescribing pattern variation to compare medications for type 2 diabetes.
Prentice JC; Conlin PR; Gellad WF; Edelman D; Lee TA; Pizer SD
Value Health; 2014 Dec; 17(8):854-62. PubMed ID: 25498781
[TBL] [Abstract][Full Text] [Related]
5. All-Cause and Cause-Specific Mortality among Users of Basal Insulins NPH, Detemir, and Glargine.
Strandberg AY; Hoti FJ; Strandberg TE; Christopher S; Haukka J; Korhonen P
PLoS One; 2016; 11(3):e0151910. PubMed ID: 27031113
[TBL] [Abstract][Full Text] [Related]
6. Long-acting insulin analogues and diabetic retinopathy: a retrospective cohort study.
Lin JC; Shau WY; Lai MS
Clin Ther; 2014 Sep; 36(9):1255-68. PubMed ID: 25082730
[TBL] [Abstract][Full Text] [Related]
7. Randomized controlled trial of insulin detemir versus NPH for the treatment of pregnant women with diabetes.
Herrera KM; Rosenn BM; Foroutan J; Bimson BE; Al Ibraheemi Z; Moshier EL; Brustman LE
Am J Obstet Gynecol; 2015 Sep; 213(3):426.e1-7. PubMed ID: 26070699
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of insulin detemir compared with NPH insulin in people with type 2 diabetes in Denmark, Finland, Norway, and Sweden.
Ridderstråle M; Jensen MM; Gjesing RP; Niskanen L
J Med Econ; 2013; 16(4):468-78. PubMed ID: 23384160
[TBL] [Abstract][Full Text] [Related]
9. Severe Hypoglycemia Risk With Long-Acting Insulin Analogs vs Neutral Protamine Hagedorn Insulin.
Bradley MC; Chillarige Y; Lee H; Wu X; Parulekar S; Muthuri S; Wernecke M; MaCurdy TE; Kelman JA; Graham DJ
JAMA Intern Med; 2021 May; 181(5):598-607. PubMed ID: 33646277
[TBL] [Abstract][Full Text] [Related]
10. Risk of diabetic foot ulceration during treatment with insulin glargine and NPH insulin.
Kostev K; Dippel FW; Rockel T; Siegmund T
J Wound Care; 2012 Oct; 21(10):483-4, 486-9. PubMed ID: 23103482
[TBL] [Abstract][Full Text] [Related]
11. A retrospective study comparing neutral protamine hagedorn insulin with glargine as basal therapy in prednisone-associated diabetes mellitus in hospitalized patients.
Dhital SM; Shenker Y; Meredith M; Davis DB
Endocr Pract; 2012; 18(5):712-9. PubMed ID: 22784834
[TBL] [Abstract][Full Text] [Related]
12. The association of long-acting insulin analogue use versus neutral protamine Hagedorn insulin use and the risk of major adverse cardiovascular events among individuals with type 2 diabetes: A population-based cohort study.
Brunetti VC; Yu OHY; Platt RW; Filion KB
Diabetes Obes Metab; 2022 Nov; 24(11):2169-2181. PubMed ID: 35726454
[TBL] [Abstract][Full Text] [Related]
13. Long-acting insulin analogues and the risk of diabetic retinopathy among patients with type 2 diabetes: A population-based cohort study.
Larose S; Filliter C; Platt RW; Yu OHY; Filion KB
Diabetes Obes Metab; 2023 Aug; 25(8):2279-2289. PubMed ID: 37165960
[TBL] [Abstract][Full Text] [Related]
14. Willingness-to-pay for benefits associated with basal insulin treatment of type 2 diabetes.
Jendle J; Ridderstråle M; Torfvitt O; Ericsson A; Larsen S
J Med Econ; 2012; 15(2):261-3. PubMed ID: 22142237
[TBL] [Abstract][Full Text] [Related]
15. Real-World Analysis of Long-Acting and NPH-Containing Insulins on Glycemic Control.
Hale G; Marcellus V; Benny T; Moreau C; Rosario E; Perez A
Sr Care Pharm; 2024 Jan; 39(1):42-49. PubMed ID: 38160236
[No Abstract] [Full Text] [Related]
16. Revisiting the efficacy of long-acting insulin analogues on adults with type 1 diabetes using mixed-treatment comparisons.
Sanches AC; Correr CJ; Venson R; Pontarolo R
Diabetes Res Clin Pract; 2011 Dec; 94(3):333-9. PubMed ID: 21992870
[TBL] [Abstract][Full Text] [Related]
17. Cancer incidence among those initiating insulin therapy with glargine versus human NPH insulin.
Stürmer T; Marquis MA; Zhou H; Meigs JB; Lim S; Blonde L; Macdonald E; Wang R; Lavange LM; Pate V; Buse JB
Diabetes Care; 2013 Nov; 36(11):3517-25. PubMed ID: 23877991
[TBL] [Abstract][Full Text] [Related]
18. Long-Term Use of Long-Acting Insulin Analogs and Breast Cancer Incidence in Women With Type 2 Diabetes.
Wu JW; Azoulay L; Majdan A; Boivin JF; Pollak M; Suissa S
J Clin Oncol; 2017 Nov; 35(32):3647-3653. PubMed ID: 28953430
[TBL] [Abstract][Full Text] [Related]
19. Long-term cost-effectiveness of insulin detemir versus NPH insulin in type 2 diabetes in Sweden.
Smith-Palmer J; Fajardo-Montañana C; Pollock RF; Ericsson A; Valentine WJ
J Med Econ; 2012; 15(5):977-86. PubMed ID: 22563742
[TBL] [Abstract][Full Text] [Related]
20. Treatment persistence in the use of basal insulins in Poland and Germany
.
Rathmann W; Czech M; Franek E; Kostev K
Int J Clin Pharmacol Ther; 2017 Feb; 55(2):119-125. PubMed ID: 27879196
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
